GW766994 is a selective, competitive antagonist of the human CC chemokine receptor-3 (CCR3).
It is proposed that the inhibition of the CCR3 receptor may provide a treatment for airway
inflammation such as in asthma. This will be a double-blind, placebo controlled, parallel
group study being conducted to evaluate the effects of GW766994 in subjects with
mild-moderate asthma who have high sputum eosinophilia. The primary objective is to compare
the effects of GW766994 to placebo on sputum eosinophils.